A physician holds a clipboard and a patient gestures towards it. A physician holds a clipboard and a patient gestures towards it.

Veracyte’s approach to prostate cancer testing

About treatment decision-making for patients with prostate cancer

Prostate cancer is one of the most common cancers in men worldwide. In the US, 288,300 men are expected to be diagnosed with prostate cancer in 2023 and 34,700 men are expected to die from the disease.1 Localized prostate cancer can vary widely, ranging from slow-growing to highly aggressive disease. Identifying the most appropriate treatment is critical to improving outcomes.

Prostate cancer may be treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments, depending on the stage and severity of the cancer. Historically, treatment was primarily selected based on clinical and pathological factors such as prostate-specific antigen (PSA) level, Gleason score and stage, as well as patient preference. Use of clinical factors alone for risk stratification, which have limited accuracy, can lead to over- and under-treatment of patients with localized prostate cancer.

At Veracyte, we aim to help physicians better personalize treatment for prostate cancer patients with tests that evaluate the molecular makeup of their tumor.


men are expected to be diagnosed with prostate cancer in the US in 2023.1


men are expected to die of prostate cancer in 2023 in the US.1


Learn about our exceptional prognostic test for prostate cancer.

Identifying unmet needs through listening and collaboration

At Veracyte, we know from our close collaboration with our customers and the research community that guiding care for patients with prostate cancer can be challenging. Key questions they face focus on who to treat, when to treat, and how aggressively to treat. Veracyte is committed to developing tests that empower physicians with the insights they need to confidently navigate treatment planning with their patients. We also continually seek a greater understanding of prostate cancer biology so that we may help answer additional key clinical questions with our innovative offerings.

Selecting a prostate cancer management strategy is a nuanced process, balancing the oncologic benefits of treatments with their impacts on quality of life. Our goal as physicians is to make sure the right patients are getting the right treatment at the right time.”

Associate Professor of Urology and Clinical Director for the Polsky Urological Oncology Center, Northwestern Feinberg School of Medicine

An older Black man holds medical information, which he reviews with a physician who is a woman with light skin.


Better treatment planning with the Decipher® Prostate Genomic Classifier

Veracyte developed the Decipher Prostate Genomic Classifier to help physicians and their patients with prostate cancer determine the best treatment plan. The test does this by determining how aggressive the patient’s cancer is and identifying how likely the cancer is to metastasize. Armed with this information, the physician may recommend less intensive treatment or earlier, more intensive treatment.2-16 Decipher Prostate was developed using whole-transcriptome analysis and machine learning and is performed on a sample taken during biopsy or surgical removal of the prostate.

An older Black couple dancing.

Learn about Decipher Prostate for prostate cancer


  1. American Cancer Society. Cancer Facts & Figures 2023.

  2. Vince Jr RA, et al. Prostate Cancer Prostatic Dis. 2021.

  3. Kim HL, et al. Prostate Cancer Prostatic Dis. 2019.

  4. Herlemann A, et al. Prostate Cancer Prostatic Dis. 2020

  5. Berlin A, et al. Int J Radiat Oncol Biol Phys. 2019.

  6. Spratt DE, et al. J Clin Oncol. 2018.

  7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [June 20, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN = National Comprehensive Cancer Network® (NCCN®).

  8. Spratt DE, et al. J Clin Oncol. 2022.

  9. Nguyen PL, et al. Prostate Cancer Prostatic Dis. 2017.

  10. Nguyen PL, et al. Int J Radiat Oncol Biol Phys. 2023.

  11. Den RB, et al. J Clin Oncol. 2015.

  12. Ross AE, et al. Prostate Cancer Prostatic Dis. 2016.

  13. Marascio J, et al. Prostate Cancer Prostatic Dis. 2019.

  14. Feng FY, et al. JAMA Oncol. 2021.

  15. Spratt DE, et al. Eur Urol. 2018.

  16. Dal Pra A, et al. Ann Oncol. 2022.

The Decipher Prostate Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.